ARS Pharmaceuticals Partners with Drew Brees to Promote Neffy Nasal Spray for 40M Allergy Patients
SPRY•ARS Pharmaceuticals has launched a collaboration with Drew Brees to educate approximately 40 million Americans with type I allergies on emergency use of neffy nasal spray. The campaign emphasizes needle-free epinephrine readiness and aims to boost awareness of treatment options for severe allergic reactions, including anaphylaxis.
1. Partnership with Drew Brees
ARS Pharmaceuticals has engaged Hall of Famer Drew Brees, who was diagnosed with peanut and other food allergies, to lead a national awareness campaign. Brees will share personal insights on managing severe allergic reactions and the importance of preparedness in daily life.
2. neffy Nasal Spray Features
neffy is an FDA-approved epinephrine nasal spray indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adults and children weighing at least 33 pounds. The needle-free design aims to reduce hesitation during allergic emergencies and provides a second-dose option five minutes after initial use.
3. Education Campaign Details
The campaign will target approximately 40 million Americans living with type I allergies, including 33 million with food allergies, through real-world scenarios—family meals, workouts and travel. It will emphasize proactive planning, communication with caregivers and avoiding delayed treatment by increasing epinephrine readiness.
4. Implications for ARS Pharmaceuticals
By leveraging Brees’s credibility and reach, ARS Pharmaceuticals aims to boost neffy brand recognition and drive product adoption ahead of back-to-school and summer camp seasons. Enhanced awareness could translate into higher prescription volumes and stronger market positioning in the epinephrine emergency treatment segment.
